DeepCurrents Investment Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

DeepCurrents Investment Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-205	Closed	-$1.79M	–	138
2024 Q1	$1.79M	Hold	205	–	–	0.07%	135
2023 Q4	$1.98M	Buy	+205	New	+$18.1K	0.07%	129
2023 Q2	–	Sell	-350	Closed	-$3.4M	–	148
2023 Q1	$3.4M	Buy	+350	New	+$36.3K	0.13%	110
2020 Q2	–	Sell	-3,900	Closed	-$330K	–	127
2020 Q1	$330K	Sell	3,900 -23,400	-86%	-$2.02M	0.02%	114
2019 Q4	$2.31M	Buy	+27,300	New	+$2.06M	0.1%	76
2019 Q2	–	Sell	-75,000	Closed	-$6.66M	–	88
2019 Q1	$6.66M	Buy	75,000 +35,000	+88%	+$3.24M	0.58%	38
2018 Q4	$3.41M	Buy	+40,000	New	+$3.81M	0.42%	45

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DeepCurrents Investment Group's BMRN Position: Q1 2025 in Review

DeepCurrents Investment Group sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 51,249 shares — an estimated $3.37M sold.

DeepCurrents Investment Group first reported a position in BMRN in Q4 2018 and held it in 18 quarters. The position peaked at $19.4M in Q4 2022. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

DeepCurrents Investment Group reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
DeepCurrents Investment Group sold 51,249 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $3.37M.
DeepCurrents Investment Group first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 18 quarters.
DeepCurrents Investment Group's BioMarin Pharmaceuticals position peaked at $19.4M in Q4 2022.
584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on DeepCurrents Investment Group's 13F filing for Q1 2025, filed 15 May 2025.